/
Oncology
Squamous Cell Carcinoma
186
Pipeline Programs↗
246
Active Trials↗
101
Companies Involved↗
Squamous Cell Carcinoma is a highly competitive landscape with 186 programs across 101 companies. The most active players are Incyte, Incyte Biosciences International Sàrl, Iovance Biotherapeutics, Inc.. 35 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical35
Phase 128
Phase 288
Phase 335
Approved
No programs
Analysis
Modality Breakdown
74%
Small molecule
127 of 172 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 172 classified programs, each share of the total. Modality classified for 97% of 186 pipeline programs.
Analysis
Trial Status
741
clinical trials
Completed275 · 37%
Recruiting118 · 16%
Terminated99 · 13%
Unknown status81 · 11%
Active, not recruiting63 · 9%
Not yet recruiting54 · 7%
Other51 · 7%
Clinical Trials
Trial Activity
741 trials
Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT03374215·1,150 enrolled
Total Pancreatectomy With Islet Autotransplantation (TPIAT) for Patients With Periampullary Neoplasms at High Risk for Pancreaticojejunostomy Leakage After Pancreaticoduodenectomy: a Single-center, Prospective, Single-Arm, Observational Study
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Preclinical·NCT07360119·20 enrolled
Page 1 of 50
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)